{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-003595","form_type":"8-K","ticker":"APTOF","cik":"0000882361","company_name":"Aptose Biosciences Inc.","filed_at":"2023-05-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.582867+00:00","generated_at":"2026-06-14T13:46:59.218514+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aptose Biosciences enters $25M committed equity facility with Keystone Capital Partners","bullets":["Up to $25M in common shares may be sold over 24 months at Company's discretion.","377,336 commitment shares issued to Keystone as consideration for the facility.","Fixed purchases limited to 50,000 shares/day at price >= $0.25; VWAP purchases allowed.","Net proceeds to be used for working capital and general corporate purposes.","TSX conditionally approved; facility subject to Nasdaq Exchange Cap and other conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-003595","json":"https://secwatch.observer/filing/0001171843-23-003595.json","markdown":"https://secwatch.observer/filing/0001171843-23-003595.md","text":"https://secwatch.observer/filing/0001171843-23-003595.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882361/000117184323003595/0001171843-23-003595-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882361/000117184323003595/f8k_052523.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T13:46:59.218514+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"aa63cec9d544193b03007519695b52daee521681","claim":"Aptose Biosciences Inc. entered into Registration Rights Agreement with Keystone Capital Partners, LLC (effective 2023-05-25).","evidence_excerpt":"Additionally, on May 25, 2023, the Company and Keystone entered into a registration rights agreement (the “ Registration Rights Agreement ”), pursuant to which the Company agreed to file a registration statement with the United States Securities and Exchange Commission (“ SEC ”) covering the resale of Common Shares that are issued to Keystone under the Purchase Agreement.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882361/000117184323003595/0001171843-23-003595-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"Keystone Capital Partners, LLC"},{"label":"Effective","value":"2023-05-25"}],"fact_type":"material_agreement"},{"claim_id":"fe0ee76b5b912a253d5e0ab9b5f9ce52dc646255","claim":"Aptose Biosciences Inc. entered into Purchase Agreement with Keystone Capital Partners, LLC valued at $25,000,000 (effective 2023-05-25).","evidence_excerpt":"On May 25, 2023, Aptose Biosciences Inc. (the “ Company ”) and Keystone Capital Partners, LLC (“ Keystone ”), entered into a common share purchase agreement (the “ Purchase Agreement ”), which provides that subject to the terms and conditions set forth therein, the Company may sell to Keystone up to the lesser of (i) $25,000,000 of the Company’s common shares","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882361/000117184323003595/0001171843-23-003595-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Keystone Capital Partners, LLC"},{"label":"Value","value":"$25,000,000"},{"label":"Effective","value":"2023-05-25"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}